BACKGROUND: dequate staging is essential in @entity1 with @entity298 ( @entity298 ) from @entity14 ( @entity14 ) who are candidates for @entity1104 ( @entity1104 ) followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Metabolic imaging using @entity419 -PET-CT is commonly used to exclude distant @entity3 in these @entity1 . Here, we aimed to assess the performance of @entity419 -PET-CT in locoregional staging of the extent of @entity298 . METHODS: @entity1 with @entity298 from @entity14 underwent staging including @entity419 -PET-CT. In the absence of @entity6831 , @entity1104 and @entity901 based HIPEC were performed. The extent of @entity298 was quantified during surgery using the modified 7 region count (7RC). The correlation between imaging based estimation of @entity298 extent and surgical 7RC was analyzed using Pearson correlation using both @entity1 based and region based analyses. RESULTS: Fifty-five @entity1 were included between February 2005 and October 2018. Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were 57%, 98%, 95%, 78% and 82% respectively for @entity5 and 32%, 100%, 100%, 55% and 63% respectively. @entity419 -PET-CT detected the presence of colorectal @entity298 in 96% of @entity1 suffering from @entity298 with nonmucinous histology and in 60% of @entity1 suffering from @entity298 with mucinous histology. Correlation between imaging 7RC and surgical 7RC was better for @entity298 with nonmucinous histology (r = 0.623) than for @entity298 with mucinous histology (r = -0.180). CONCLUSIONS: Despite of underestimating the exact extent of disease involvement, @entity419 -PET-CT shows good performance in detecting colorectal @entity298 with nonmucinous histology. For colorectal @entity298 with mucinous histology, @entity419 -PET-CT, however, shows poor performance. Since @entity419 -PET-CT did not detect the presence of colorectal @entity298 in all @entity1 in whom long-term survival could be achieved, @entity419 -PET-CT should be implemented into a broad pre-operative assessment strategy.

Clinical Value of XXXX - PET-CT in the Preoperative Staging of Peritoneal Carcinomatosis from Colorectal Origin.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity901 :: ('MESH:C030110', 'Chemical') :: ['oxaliplatin'] @entity419 :: ('MESH:D019788', 'Chemical') :: ['(18)F-FDG', '18F-FDG'] @entity5 :: ('MESH:D009369', 'Disease') :: ['non-mucinous tumors'] @entity6831 :: ('MESH:D004673', 'Disease') :: ['systemic -dissemination'] @entity14 :: ('MESH:D015179', 'Disease') :: ['CRC', 'colorectal cancer'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis'] @entity1104 :: ('MESH:D000267', 'Disease') :: ['CRS', 'cytoreductive surgery'] @entity298 :: ('MESH:D010538', 'Disease') :: ['peritoneal carcinomatosis', 'PC']
@entity419 :: (MESH:D019788,Chemical) :: ['(18)F-FDG']
